{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:50:46Z","timestamp":1792673446416,"version":"4.5.0"},"reference-count":204,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Tuberculosis (TB) remains a leading infectious killer, increasingly complicated by multidrug-resistant (MDR) and extensively drug-resistant (XDR) disease; current regimens, although effective, are prolonged, toxic, and often fail to reach intracellular bacilli in heterogeneous lung lesions. This narrative review synthesizes how next-generation antimycobacterial strategies can be translated \u201cfrom molecule to patient\u201d by coupling potent therapeutics with delivery platforms tailored to the lesion microenvironment. We survey emerging small-molecule classes, including decaprenylphosphoryl-\u03b2-D-ribose 2\u2032-epimerase (DprE1) inhibitors, mycobacterial membrane protein large 3 (MmpL3) inhibitors, and respiratory chain blockers, alongside optimized uses of established agents and host-directed therapies (HDTs). These are mapped to inhalable and nanocarrier systems that improve intralesional exposure, macrophage uptake, and targeted release while reducing systemic toxicity. Particular emphasis is placed on pulmonary dry powder inhalers (DPIs) and aerosols for direct lung targeting, stimuli-responsive carriers that trigger release through pH, redox, or enzymatic cues, and long-acting depots or implants that shift daily dosing to monthly or quarterly schedules to enhance adherence, safety, and access. We also outline translational enablers, including model-informed pharmacokinetic\/pharmacodynamic (PK\/PD) integration, device formulation co-design, manufacturability, regulatory quality frameworks, and patient-centered implementation. Overall, aligning stronger drugs with smart delivery platforms offers a practical pathway to shorter, safer, and more easily completed TB therapy, improving both individual outcomes and public health impact.<\/jats:p>","DOI":"10.3390\/pharmaceutics18010060","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T12:23:44Z","timestamp":1767356624000},"page":"60","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Advancing Tuberculosis Treatment with Next-Generation Drugs and Smart Delivery Systems"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7726-9532","authenticated-orcid":false,"given":"Ayman","family":"Elbehiry","sequence":"first","affiliation":[{"name":"Department of Public Health, College of Applied Medical Sciences, Qassim University, P.O. Box 6666, Buraydah 51452, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1699-6263","authenticated-orcid":false,"given":"Eman","family":"Marzouk","sequence":"additional","affiliation":[{"name":"Department of Public Health, College of Applied Medical Sciences, Qassim University, P.O. Box 6666, Buraydah 51452, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2294-9837","authenticated-orcid":false,"given":"Adil","family":"Abalkhail","sequence":"additional","affiliation":[{"name":"Department of Public Health, College of Applied Medical Sciences, Qassim University, P.O. Box 6666, Buraydah 51452, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,1]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (WHO) (2024). Global Tuberculosis Report 2024, World Health Organization. Available online: https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2024."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Yang, H., Ruan, X., Li, W., Xiong, J., and Zheng, Y. (2024). Global, regional, and national burden of tuberculosis and attributable risk factors for 204 countries and territories, 1990\u20132021: A systematic analysis for the Global Burden of Diseases 2021 study. BMC Public Health, 24.","DOI":"10.1186\/s12889-024-20664-w"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"107279","DOI":"10.1016\/j.ijid.2024.107279","article-title":"Disparities in tuberculosis diagnostic delays between native and migrant populations in Italy: A multicenter study","volume":"150","author":"Cotugno","year":"2025","journal-title":"Int. J. Infect. Dis."},{"key":"ref_4","unstructured":"Pan American Health Organization (PAHO) (2024). Tuberculosis Resurges as Top Infectious Disease Killer, PAHO. Available online: https:\/\/www.paho.org\/en\/news\/1-11-2024-tuberculosis-resurges-top-infectious-disease-killer?."},{"key":"ref_5","unstructured":"World Health Organization (WHO) (2022). Consolidated Guidelines on Tuberculosis: Module 4\u2014Treatment: Drug-Susceptible Tuberculosis, World Health Organization. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240048126?."},{"key":"ref_6","unstructured":"World Health Organization (WHO) (2024). TB Knowledge Sharing Platform\u2014Treatment of Drug-Susceptible Tuberculosis, World Health Organization. Available online: https:\/\/tbksp.who.int\/es\/node\/2774?."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.15585\/mmwr.mm7108a1","article-title":"Interim guidance: 4-month rifapentine-moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis\u2014United States, 2022","volume":"71","author":"Carr","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1021\/acsinfecdis.6b00051","article-title":"Prediction of drug penetration in tuberculosis lesions","volume":"2","author":"Sarathy","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"ref_10","first-page":"581","article-title":"High-resolution matrix-assisted laser desorption ionization\u2013imaging mass spectrometry of lipids in rodent optic nerve tissue","volume":"19","author":"Anderson","year":"2013","journal-title":"Mol. Vis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/imr.12252","article-title":"Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses","volume":"264","author":"Lenaerts","year":"2015","journal-title":"Immunol. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e41115","DOI":"10.7554\/eLife.41115","article-title":"High-resolution mapping of fluoroquinolones in TB rabbit lesions reveals specific distribution in immune cell types","volume":"7","author":"Blanc","year":"2018","journal-title":"eLife"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Yilma, A., Bailey, H., Karakousis, P.C., and Karanika, S. (2023). HIV\/tuberculosis coinfection in pregnancy and the postpartum period. J. Clin. Med., 12.","DOI":"10.3390\/jcm12196302"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e00159-19","DOI":"10.1128\/CMR.00159-19","article-title":"Caseum: A niche for Mycobacterium tuberculosis drug-tolerant persisters","volume":"33","author":"Sarathy","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Strydom, N., Gupta, S.V., Fox, W.S., Via, L.E., Bang, H., Lee, M., Eum, S., Shim, T., Barry, C.E., and Zimmerman, M. (2019). Tuberculosis drugs\u2019 distribution and emergence of resistance in patient\u2019s lung lesions: A mechanistic model and tool for regimen and dose optimization. PLoS Med., 16.","DOI":"10.1371\/journal.pmed.1002773"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/014107680609901017","article-title":"The MRC randomized trial of streptomycin and its legacy: A view from the clinical front line","volume":"99","author":"Crofton","year":"2006","journal-title":"J. R. Soc. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e01586-16","DOI":"10.1128\/mBio.01586-16","article-title":"Origins of combination therapy for tuberculosis: Lessons for future antimicrobial development and application","volume":"8","author":"Kerantzas","year":"2017","journal-title":"mBio"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1513\/AnnalsATS.201509-632PS","article-title":"Treatment of tuberculosis. A historical perspective","volume":"12","author":"Murray","year":"2015","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"105132","DOI":"10.1016\/j.cmicom.2025.105132","article-title":"Building on the past: Revisiting historical tuberculosis trials in a modern era","volume":"2","author":"Dahl","year":"2025","journal-title":"CMI Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S402","DOI":"10.1093\/clinids\/5.Supplement_3.S402","article-title":"History of the development of rifampin","volume":"5","author":"Sensi","year":"1983","journal-title":"Rev. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"fuac051","DOI":"10.1093\/femsre\/fuac051","article-title":"What the Hel: Recent advances in understanding rifampicin resistance in bacteria","volume":"47","author":"Borah","year":"2023","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_22","unstructured":"U.S. Food and Drug Administration (FDA) (2025, October 10). SIRTURO (Bedaquiline) Tablets\u2014NDA Approval Letter, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2012\/204384Orig1s000ltr.pdf."},{"key":"ref_23","unstructured":"European Medicines Agency (EMA) (2024). Deltyba, INN\u2014Delamanid: Product Information (EPAR), European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/deltyba-epar-product-information_en.pdf?."},{"key":"ref_24","unstructured":"U.S. Food and Drug Administration (FDA) (2025, October 26). Pretomanid Tablets\u2014NDA 212862 Approval Package, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212862Orig1s000Approv.pdf?."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1007\/s13346-022-01238-y","article-title":"A review of formulations and preclinical studies of inhaled rifampicin for its clinical translation","volume":"13","author":"Khadka","year":"2023","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"102228","DOI":"10.1016\/j.tube.2022.102228","article-title":"Dry powder inhalers of antitubercular drugs","volume":"135","author":"Nainwal","year":"2022","journal-title":"Tuberculosis"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Buya, A.B., Witika, B.A., Bapolisi, A.M., Mwila, C., Mukubwa, G.K., Memvanga, P.B., Makoni, P.A., and Nkanga, C.I. (2021). Application of lipid-based nanocarriers for antitubercular drug delivery: A review. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13122041"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Kumar, M., Virmani, T., Kumar, G., Deshmukh, R., Sharma, A., Duarte, S., Brand\u00e3o, P., and Fonte, P. (2023). Nanocarriers in tuberculosis treatment: Challenges and delivery strategies. Pharmaceuticals, 16.","DOI":"10.3390\/ph16101360"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"124608","DOI":"10.1016\/j.ijpharm.2024.124608","article-title":"Development of a proliposomal pretomanid dry powder inhaler as a novel alternative approach for combating pulmonary tuberculosis","volume":"664","author":"Aekwattanaphol","year":"2024","journal-title":"Int. J. Pharm."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"123920","DOI":"10.1016\/j.ijpharm.2024.123920","article-title":"A quality-by-design strategic approach for the development of bedaquiline-pretomanid nanoparticles as inhalable dry powders for TB treatment","volume":"653","author":"Patil","year":"2024","journal-title":"Int. J. Pharm."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Bera, H., Zhao, C., Tian, X., Cun, D., and Yang, M. (2024). Mannose-decorated solid-lipid nanoparticles for alveolar macrophage targeted delivery of rifampicin. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16030429"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1186\/s12951-024-02875-w","article-title":"Nanomaterial-mediated host directed therapy of tuberculosis by manipulating macrophage autophagy","volume":"22","author":"Liu","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s40001-025-02443-4","article-title":"Host-directed therapy for tuberculosis","volume":"30","author":"Tian","year":"2025","journal-title":"Eur. J. Med. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S510","DOI":"10.1093\/cid\/ciac672","article-title":"Potential impact of long-acting products on the control of tuberculosis: Preclinical advancements and translational tools in preventive treatment","volume":"75","author":"Ammerman","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/17425247.2019.1551875","article-title":"Use of computational fluid dynamics deposition modeling in respiratory drug delivery","volume":"16","author":"Longest","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.1038\/s41598-024-56033-1","article-title":"Validation of computational fluid dynamics models for airway deposition with SPECT data of the same population","volume":"14","author":"Sadafi","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_37","unstructured":"Long-Acting\/Extended Release Antiretroviral Resource Program (LEAP) (2024). Long-Acting Tuberculosis Drug Development Workshop 2024, LEAP. Available online: https:\/\/longactinghiv.org\/LEAP-TB-WORKSHOP-2024?."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"276","DOI":"10.5588\/ijtldopen.24.0670","article-title":"Patient and provider preferences for long-acting TB preventive therapy","volume":"2","author":"Vermeulen","year":"2025","journal-title":"IJTLD Open"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2469333","DOI":"10.1080\/21645515.2025.2469333","article-title":"RNA vaccines: The dawn of a new age for tuberculosis?","volume":"21","author":"Li","year":"2025","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"a021147","DOI":"10.1101\/cshperspect.a021147","article-title":"Tuberculosis drug development: History and evolution of the mechanism-based paradigm","volume":"5","author":"Chakraborty","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e202300099","DOI":"10.1002\/cmdc.202300099","article-title":"DprE1 inhibitors: Enduring aspirations for future antituberculosis drug discovery","volume":"18","author":"Yadav","year":"2023","journal-title":"ChemMedChem"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/17460441.2023.2218082","article-title":"Recent advances in mycobacterial membrane protein large 3 inhibitor drug design for mycobacterial infections","volume":"18","author":"North","year":"2023","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.cmi.2024.06.016","article-title":"Candidate anti-tuberculosis medicines and regimens under clinical evaluation","volume":"30","author":"Hoelscher","year":"2024","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.apsb.2025.01.023","article-title":"Revolutionizing tuberculosis treatment: Breakthroughs, challenges, and hope on the horizon","volume":"15","author":"Kufa","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13063-024-07912-5","article-title":"Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: Protocol for a multicenter, phase 2b\/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy","volume":"25","author":"Dawson","year":"2024","journal-title":"Trials"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"100952","DOI":"10.1016\/j.lanmic.2024.07.015","article-title":"Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043\u201302): An open-label, dose-expansion, randomised, controlled, phase 1b\/2a trial","volume":"6","author":"Heinrich","year":"2025","journal-title":"Lancet Microbe"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41591-024-02829-7","article-title":"A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: A phase 2a open-label, randomized trial","volume":"30","author":"Diacon","year":"2024","journal-title":"Nat. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e01562-23","DOI":"10.1128\/aac.01562-23","article-title":"Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis","volume":"68","author":"Li","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_49","unstructured":"World Health Organization (WHO) (2022). WHO Consolidated Guidelines on Tuberculosis: Module 4\u2014Treatment: Drug-Resistant Tuberculosis Treatment (2022 Update), World Health Organization. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240063129?."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1016\/S2666-5247(23)00317-8","article-title":"Opportunities and limitations of genomics for diagnosing bedaquiline-resistant tuberculosis: A systematic review and individual isolate meta-analysis","volume":"5","author":"Nimmo","year":"2024","journal-title":"Lancet Microbe"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2300639","DOI":"10.1183\/13993003.00639-2023","article-title":"Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: A systematic review and meta-analysis","volume":"62","author":"Perumal","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e00854-24","DOI":"10.1128\/aac.00854-24","article-title":"Frameshift mutations in the mmpR5 gene can have a bedaquiline-susceptible phenotype by retaining a protein structure and function similar to wild-type Mycobacterium tuberculosis","volume":"68","author":"Snobre","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e02183-24","DOI":"10.1128\/mbio.02183-24","article-title":"Allosteric coupling of substrate binding and proton translocation in MmpL3 transporter from Mycobacterium tuberculosis","volume":"15","author":"Babii","year":"2024","journal-title":"mBio"},{"key":"ref_54","unstructured":"World Health Organization (WHO) (2024). Section 1.3: Drug-Resistant Tuberculosis. Global Tuberculosis Report 2024, World Health Organization. Available online: https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2024\/tb-disease-burden\/1-3-drug-resistant-tb."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e00531-22","DOI":"10.1128\/aac.00531-22","article-title":"Spontaneous mutational patterns and novel mutations for delamanid resistance in Mycobacterium tuberculosis","volume":"66","author":"Liu","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e00513-20","DOI":"10.1128\/AAC.00513-20","article-title":"Natural polymorphisms in Mycobacterium tuberculosis conferring resistance to delamanid in drug-naive patients","volume":"64","author":"Reichmuth","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"26551","DOI":"10.1021\/acsomega.5c00610","article-title":"High-Level Primary Pretomanid-Resistant with ddn In-Frame Deletion of Mycobacterium tuberculosis and Its Association with Lineage 4.5 in China","volume":"10","author":"Pei","year":"2025","journal-title":"ACS Omega"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline\u2013pretomanid\u2013linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1473-3099(24)00601-7","article-title":"Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: A randomised, active-controlled, open-label trial","volume":"25","author":"Dawson","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_61","unstructured":"Holtzman, D., de Jager, V., Dawson, R., Narunsky, K., Moloantoa, T., Venter, E., Stinson, K., Levi, M., Anderson, A., and Grekas, E. (2023, January 15\u201318). A randomized, active-control, open-label Phase 2a trial evaluating the bactericidal activity, safety, and pharmacokinetics of TBA-7371 in drug-susceptible pulmonary tuberculosis. Proceedings of the World Conference on Lung Health 2023, Paris, France. Available online: https:\/\/www.gatesmri.org\/wp-content\/uploads\/2024\/02\/tbd03-201-union-late-breaker-abstract.pdf."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S1473-3099(25)00213-0","article-title":"Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): A prospective, open-label, randomised, phase 2b dose-finding trial","volume":"25","author":"Heinrich","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1164\/rccm.202408-1632OC","article-title":"Telacebec, a Potent Agent in the Fight Against Tuberculosis: Findings from A Randomized, Phase 2 Clinical Trial and Beyond","volume":"211","author":"Janssen","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_64","unstructured":"(2025, October 27). Phase 2a Study to Evaluate the Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203). New TB Drugs. Available online: https:\/\/www.newtbdrugs.org\/pipeline\/trials\/phase-2-telacebec-q203-eba?."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1128\/AAC.00037-14","article-title":"Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis","volume":"58","author":"Hartkoorn","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"102969","DOI":"10.1016\/j.bioorg.2019.102969","article-title":"Current development of 5-nitrofuran-2-yl derivatives as antitubercular agents","volume":"88","author":"Elsaman","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"103587","DOI":"10.1016\/j.bioorg.2020.103587","article-title":"Single-step synthesis and in vitro anti-mycobacterial activity of novel nitrofurantoin analogues","volume":"96","author":"Zuma","year":"2020","journal-title":"Bioorg Chem."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Bruhn, D.F., Scherman, M.S., Woolhiser, L.K., Madhura, D.B., Maddox, M.M., Singh, A.P., Lee, R.B., Hurdle, J.G., and McNeil, M.R. (2014). Pentacyclic nitrofurans with in vivo efficacy and activity against nonreplicating Mycobacterium tuberculosis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087909"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Komarova, K., Vinogradova, L., Lukin, A., Zhuravlev, M., Deniskin, D., Chudinov, M., Gureev, M., Dogonadze, M., Zabolotnykh, N., and Vinogradova, T. (2024). The Nitrofuran-Warhead-Equipped Spirocyclic Azetidines Show Excellent Activity against Mycobacterium tuberculosis. Molecules, 29.","DOI":"10.3390\/molecules29133071"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/jac\/dkaf076","article-title":"Population pharmacokinetics and exposure\u2013response relationship of the antituberculosis drug BTZ-043","volume":"80","author":"Koele","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e00024-21","DOI":"10.1128\/AAC.00024-21","article-title":"Pharmacokinetics and target attainment of SQ109 in plasma and human-like tuberculosis lesions in rabbits","volume":"65","author":"Egbelowo","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1021\/acs.jcim.3c00616","article-title":"Inhibition mechanism of anti-TB drug SQ109: Allosteric inhibition of TMM translocation of Mycobacterium tuberculosis MmpL3 transporter","volume":"63","author":"Carbone","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMc1913327","article-title":"Telacebec (Q203), a new antituberculosis agent","volume":"382","author":"Dawson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e01123-22","DOI":"10.1128\/aac.01123-22","article-title":"Safety, tolerability, pharmacokinetics, and metabolism of Telacebec (Q203) for the treatment of tuberculosis: A randomized, placebo-controlled, multiple ascending dose phase 1B trial","volume":"67","author":"Kim","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Chauffour, A., Cambau, E., Pethe, K., Veziris, N., and Aubry, A. (2025). Unprecedented in vivo activity of telacebec against Mycobacterium leprae. PLoS Neglected Trop. Dis., 19.","DOI":"10.1371\/journal.pntd.0013076"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cmi.2023.07.013","article-title":"Recent advances in the treatment of tuberculosis","volume":"30","author":"Motta","year":"2024","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Chen, R.H., Burke, A., Cho, J.-G., Alffenaar, J.-W., and Davies Forsman, L. (2024). New oxazolidinones for tuberculosis: Are novel treatments on the horizon?. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16060818"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e02451-21","DOI":"10.1128\/spectrum.02451-21","article-title":"The novel oxazolidinone TBI-223 is effective in three preclinical mouse models of methicillin-resistant Staphylococcus aureus infection","volume":"10","author":"Gordon","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"7311","DOI":"10.1038\/s41467-024-50781-4","article-title":"Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen","volume":"15","author":"Strydom","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e01542-24","DOI":"10.1128\/aac.01542-24","article-title":"Pharmacokinetics, tolerability, and safety of TBI-223, a novel oxazolidinone, in healthy participants","volume":"69","author":"Lombardi","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3201\/eid2608.191499","article-title":"Linezolid-associated neurologic adverse events in patients with multidrug-resistant tuberculosis, France","volume":"26","author":"Jaspard","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"105020","DOI":"10.1016\/j.micinf.2022.105020","article-title":"Impacts of clofazimine on the treatment outcomes of drug-resistant tuberculosis","volume":"25","author":"Wang","year":"2023","journal-title":"Microbes Infect."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.5588\/ijtld.12.0144","article-title":"Systematic review of clofazimine for the treatment of drug-resistant tuberculosis","volume":"17","author":"Gopal","year":"2013","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1164\/rccm.202407-1354OC","article-title":"Efficacy and safety of higher doses of levofloxacin for multidrug-resistant tuberculosis: A randomized, placebo-controlled phase II clinical trial","volume":"211","author":"Phillips","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1128\/AAC.05690-11","article-title":"Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo","volume":"56","author":"England","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1183\/13993003.00214-2016","article-title":"Comparison of effectiveness and safety of imipenem\/clavulanate-versus meropenem\/clavulanate-containing regimens in the treatment of MDR-and XDR-TB","volume":"47","author":"Tiberi","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/cid\/cix819","article-title":"Metformin use reverses the increased mortality associated with diabetes mellitus during tuberculosis treatment","volume":"66","author":"Degner","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3904\/kjim.2023.303","article-title":"Relationship between metformin use and mortality in tuberculosis patients with diabetes: A nationwide cohort study","volume":"39","author":"Chung","year":"2024","journal-title":"Korean J. Intern. Med."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Tetteh, P., Danso, E.K., Osei-Wusu, S., Yeboah-Manu, D., and Asare, P. (2025). The role of metformin in tuberculosis control among TB and diabetes mellitus comorbid individuals. Front. Microbiol., 16.","DOI":"10.3389\/fmicb.2025.1549572"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/infdis\/jit550","article-title":"Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation","volume":"209","author":"Parihar","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e002077","DOI":"10.1136\/bmjresp-2023-002077","article-title":"Association between statin use and tuberculosis risk in patients with bronchiectasis: A retrospective population-based cohort study in Taiwan","volume":"11","author":"Liao","year":"2024","journal-title":"BMJ Open Respir. Res."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Sabeel, S., Motaung, B., Ozturk, M., Mafu, T.S., Wilkinson, R.J., Thienemann, F., and Guler, R. (2025). Immunomodulatory effects of atorvastatin on peripheral blood mononuclear cells infected with Mycobacterium tuberculosis. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1597534"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Wu, H.-x., Xiong, X.-f., Zhu, M., Wei, J., Zhuo, K.-q., and Cheng, D.-y. (2018). Effects of vitamin D supplementation on the outcomes of patients with pulmonary tuberculosis: A systematic review and meta-analysis. BMC Pulm. Med., 18.","DOI":"10.1186\/s12890-018-0677-6"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"559","DOI":"10.17305\/bb.2025.12527","article-title":"Vitamin D supplementation for tuberculosis prevention: A meta-analysis","volume":"26","author":"Liu","year":"2025","journal-title":"Biomol. Biomed."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"28171","DOI":"10.1038\/srep28171","article-title":"Autophagy induction targeting mTORC1 enhances Mycobacterium tuberculosis replication in HIV co-infected human macrophages","volume":"6","author":"Andersson","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"102047","DOI":"10.1016\/j.tube.2020.102047","article-title":"Human monocyte-derived macrophage responses to M. tuberculosis differ by the host\u2019s tuberculosis, diabetes or obesity status, and are enhanced by rapamycin","volume":"126","author":"Restrepo","year":"2021","journal-title":"Tuberculosis"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/cpdd.1402","article-title":"Pharmacokinetics of Nitazoxanide Dry Suspensions After Single Oral Doses in Healthy Subjects: Food Effects Evaluation and Bioequivalence Study","volume":"13","author":"Zhang","year":"2024","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e00167-24","DOI":"10.1128\/spectrum.00167-24","article-title":"Host-directed therapy with amiodarone in preclinical models restricts mycobacterial infection and enhances autophagy","volume":"12","author":"Boland","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Naicker, N., Sigal, A., and Naidoo, K. (2020). Metformin as host-directed therapy for TB treatment: Scoping review. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.00435"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"107379","DOI":"10.1016\/j.phrs.2024.107379","article-title":"Macrophage targeted graphene oxide nanosystem synergize antibiotic killing and host immune defense for Tuberculosis Therapy","volume":"208","author":"Pi","year":"2024","journal-title":"Pharmacol. Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1128\/IAI.01218-07","article-title":"Expression of cathelicidin LL-37 during Mycobacterium tuberculosis infection in human alveolar macrophages, monocytes, neutrophils, and epithelial cells","volume":"76","author":"Carranza","year":"2008","journal-title":"Infect. Immun."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1080\/15548627.2015.1075110","article-title":"Phenylbutyrate induces LL-37-dependent autophagy and intracellular killing of Mycobacterium tuberculosis in human macrophages","volume":"11","author":"Rekha","year":"2015","journal-title":"Autophagy"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.4049\/jimmunol.1000376","article-title":"LL-37 directs macrophage differentiation toward macrophages with a proinflammatory signature","volume":"185","author":"Beekhuizen","year":"2010","journal-title":"J. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1159\/000530083","article-title":"Regulation of macrophage cell surface GAPDH alters LL-37 internalization and downstream effects in the cell","volume":"15","author":"Dhiman","year":"2023","journal-title":"J. Innate Immun."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41541-023-00710-1","article-title":"An anti-LpqH human monoclonal antibody from an asymptomatic individual mediates protection against Mycobacterium tuberculosis","volume":"8","author":"Krishnananthasivam","year":"2023","journal-title":"npj Vaccines"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s42003-024-06006-x","article-title":"Bacteriophage therapy for the treatment of Mycobacterium tuberculosis infections in humanized mice","volume":"7","author":"Yang","year":"2024","journal-title":"Commun. Biol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s41030-022-00210-y","article-title":"Phage therapy for nontuberculous mycobacteria: Challenges and opportunities","volume":"9","author":"Hatfull","year":"2023","journal-title":"Pulm. Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.cell.2022.04.024","article-title":"Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection","volume":"185","author":"Nick","year":"2022","journal-title":"Cell"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e04597-22","DOI":"10.1128\/spectrum.04597-22","article-title":"Mycobacteriophage D29 Lysin B exhibits promising anti-mycobacterial activity against drug-resistant Mycobacterium tuberculosis","volume":"11","author":"Singh","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"9791","DOI":"10.1038\/s41467-024-54072-w","article-title":"Whole genome CRISPRi screening identifies druggable vulnerabilities in an isoniazid resistant strain of Mycobacterium tuberculosis","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Ren, W., Zhou, Y., Li, H., Shang, Y., Zhang, X., Yuan, J., Li, S., Li, C., and Pang, Y. (2023). Development and clinical evaluation of a CRISPR\/Cas13a-based diagnostic test to detect Mycobacterium tuberculosis in clinical specimens. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1117085"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Li, Q., Wang, N., Pang, M., Miao, H., Dai, X., Li, B., Yang, X., Li, C., and Liu, Y. (2024). Rapid and Highly Sensitive Detection of Mycobacterium tuberculosis Utilizing the Recombinase Aided Amplification-Based CRISPR-Cas13a System. Microorganisms, 12.","DOI":"10.3390\/microorganisms12081507"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/s41467-023-37183-8","article-title":"Genome-wide tiled detection of circulating Mycobacterium tuberculosis cell-free DNA using Cas13","volume":"14","author":"Thakku","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Lukeman, H., Al-Wassiti, H., Fabb, S.A., Lim, L., Wang, T., Britton, W.J., Steain, M., Pouton, C.W., Triccas, J.A., and Counoupas, C. (2024). A lipid nanoparticle-mRNA vaccine provides potent immunogenicity and protection against Mycobacterium tuberculosis. bioRxiv.","DOI":"10.1101\/2024.07.31.605765"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"105599","DOI":"10.1016\/j.ebiom.2025.105599","article-title":"An LNP-mRNA vaccine modulates innate cell trafficking and promotes polyfunctional Th1 CD4+ T cell responses to enhance BCG-induced protective immunity against Mycobacterium tuberculosis","volume":"113","author":"Lukeman","year":"2025","journal-title":"eBioMedicine"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41392-024-02002-z","article-title":"Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Opperman, C.J., and Brink, A.J. (2025). Phage Therapy for Mycobacteria: Overcoming Challenges, Unleashing Potential. Infect. Dis. Rep., 17.","DOI":"10.3390\/idr17020024"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5588\/ijtldopen.24.0360","article-title":"Efficacy and safety data on pretomanid for drug-resistant TB","volume":"2","author":"Thuy","year":"2025","journal-title":"IJTLD Open"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s41467-025-56146-9","article-title":"The clinical-stage drug BTZ-043 accumulates in murine tuberculosis lesions and efficiently acts against Mycobacterium tuberculosis","volume":"16","author":"Treu","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e01318-24","DOI":"10.1128\/aac.01318-24","article-title":"Real-time evaluation of macozinone activity against Mycobacterium tuberculosis through bacterial nanomotion analysis","volume":"69","author":"Vocat","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1093\/jac\/dkae266","article-title":"Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures","volume":"79","author":"Walter","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s13063-025-08973-w","article-title":"ACTG A5409 (RAD-TB): Study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosis","volume":"26","author":"Harrison","year":"2025","journal-title":"Trials"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S2213-2600(25)00194-8","article-title":"Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): An open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial","volume":"13","author":"Guglielmetti","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/cid\/ciad653","article-title":"The safety and tolerability of linezolid in novel short-course regimens containing bedaquiline, pretomanid, and linezolid to treat rifampicin-resistant tuberculosis: An individual patient data meta-analysis","volume":"78","author":"Hasan","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e03197-22","DOI":"10.1128\/spectrum.03197-22","article-title":"Atorvastatin potentially reduces mycobacterial severity through its action on lipoarabinomannan and drug permeability in granulomas","volume":"11","author":"Davuluri","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s15010-024-02446-z","article-title":"The role of vitamin D in the prevention and treatment of tuberculosis: A meta-analysis of randomized controlled trials","volume":"53","author":"Meng","year":"2025","journal-title":"Infection"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00011-025-02005-8","article-title":"Human antimicrobial\/host defense peptide LL-37 may prevent the spread of a local infection through multiple mechanisms: An update","volume":"74","author":"Svensson","year":"2025","journal-title":"Inflamm. Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"eadx2067","DOI":"10.1126\/sciadv.adx2067","article-title":"A streamlined CRISPR-based test for tuberculosis detection directly from sputum","volume":"11","author":"Bell","year":"2025","journal-title":"Sci. Adv."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"74","DOI":"10.56782\/pps.315","article-title":"Nanostructured lipid carriers applications in cosmeceuticals: Structure, formulation, safety profile and market trends","volume":"23","author":"Nadeem","year":"2025","journal-title":"Prospect. Pharm. Sci."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"105","DOI":"10.56782\/pps.280","article-title":"Advances in lopinavir formulations: Strategies to overcome solubility, bioavailability, and stability challenges","volume":"22","author":"Singireddy","year":"2024","journal-title":"Prospect. Pharm. Sci."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1080\/10837450.2023.2279691","article-title":"Review of inhalable nanoparticles for the pulmonary delivery of anti-tuberculosis drugs","volume":"28","author":"Ramachandran","year":"2023","journal-title":"Pharm. Dev. Technol."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Wang, Y., and Grainger, D.W. (2022). Regulatory considerations specific to liposome drug development as complex drug products. Front. Drug Deliv., 2.","DOI":"10.3389\/fddev.2022.901281"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Rongala, D.S., Patil, S.M., and Kunda, N.K. (2024). Design of experiment (DoE) approach for developing inhalable PLGA microparticles loaded with clofazimine for tuberculosis treatment. Pharmaceuticals, 17.","DOI":"10.3390\/ph17060754"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Galdop\u00f3rpora, J.M., Martinena, C., Bernabeu, E., Riedel, J., Palmas, L., Castangia, I., Manca, M.L., Garc\u00e9s, M., L\u00e1zaro-Martinez, J., and Salgueiro, M.J. (2022). Inhalable mannosylated rifampicin\u2013curcumin co-loaded nanomicelles with enhanced in vitro antimicrobial efficacy for an optimized pulmonary tuberculosis therapy. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14050959"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1186\/s12951-023-02156-y","article-title":"Advanced drug delivery and therapeutic strategies for tuberculosis treatment","volume":"21","author":"Nair","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"102855","DOI":"10.1016\/j.nano.2025.102855","article-title":"Liposomal drug delivery system for lung diseases: Recent advancement and future perspectives","volume":"69","author":"Bashyal","year":"2025","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"596","DOI":"10.21037\/atm-20-3946","article-title":"Administration of dry powders during respiratory supports","volume":"9","author":"Ke","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Cai, D., Gao, W., Li, Z., Zhang, Y., Xiao, L., and Xiao, Y. (2022). Current development of nano-drug delivery to target macrophages. Biomedicines, 10.","DOI":"10.3390\/biomedicines10051203"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Roque-Borda, C.A., Vishwakarma, S.K., Delgado, O.J.R., de Souza Rodrigues, H.L., Primo, L.M., Campos, I.C., De Lima, T.S., Perdig\u00e3o, J., and Pavan, F.R. (2025). Peptide-Based Strategies Against Mycobacterium tuberculosis Covering Immunomodulation, Vaccines, Synergistic Therapy, and Nanodelivery. Pharmaceuticals, 18.","DOI":"10.3390\/ph18101440"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"141740","DOI":"10.1016\/j.ijbiomac.2025.141740","article-title":"A review on biomacromolecular ligand-directed nanoparticles: New era in macrophage targeting","volume":"306","author":"Swami","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Ajayi, T.O., Poka, M.S., and Witika, B.A. (2024). Nanotechnological innovations in paediatric tuberculosis management: Current trends and future prospects. Front. Drug Deliv., 3.","DOI":"10.3389\/fddev.2023.1295815"},{"key":"ref_142","unstructured":"U.S. Food and Drug Administration (FDA) (2025, October 28). Drug Products, Including Biological Products, That Contain Nanomaterials\u2014Guidance for Industry, Available online: https:\/\/www.fda.gov\/media\/157812\/download?."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Das, S.S., Bharadwaj, P., Bilal, M., Barani, M., Rahdar, A., Taboada, P., Bungau, S., and Kyzas, G.Z. (2020). Stimuli-responsive polymeric nanocarriers for drug delivery, imaging, and theragnosis. Polymers, 12.","DOI":"10.3390\/polym12061397"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"100182","DOI":"10.1016\/j.nxnano.2025.100182","article-title":"Stimuli-responsive nanoparticles for lung disorder treatment: From serendipity to precision phosphorylation modulation and drug repurposing","volume":"7","author":"Elsayed","year":"2025","journal-title":"Next Nanotechnol."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Liu, X., He, F., and Liu, M. (2024). New opportunities of stimulus-responsive smart nanocarriers in cancer therapy. Nano Mater. Sci., in press.","DOI":"10.1016\/j.nanoms.2024.10.013"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e02266-17","DOI":"10.1128\/AAC.02266-17","article-title":"Extreme drug tolerance of Mycobacterium tuberculosis in caseum","volume":"62","author":"Sarathy","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Lin, X., Wu, J., Liu, Y., Lin, N., Hu, J., and Zhang, B. (2022). Stimuli-responsive drug delivery systems for the diagnosis and therapy of lung cancer. Molecules, 27.","DOI":"10.3390\/molecules27030948"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Naureen, F., Shah, Y., Rehman, M.u., Chaubey, P., Nair, A.K., Khan, J., Shafique, M., Shah, K.U., and Ahmad, B. (2024). Inhalable dry powder nano-formulations: Advancing lung disease therapy-a review. Front. Nanotechnol., 6.","DOI":"10.3389\/fnano.2024.1403313"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1038\/s41467-022-32043-3","article-title":"A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis","volume":"13","author":"Kim","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e00481-23","DOI":"10.1128\/aac.00481-23","article-title":"Using dynamic oral dosing of rifapentine and rifabutin to simulate exposure profiles of long-acting formulations in a mouse model of tuberculosis preventive therapy","volume":"67","author":"Chang","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"20221444","DOI":"10.1098\/rspb.2022.1444","article-title":"The risk of drug resistance during long-acting antimicrobial therapy","volume":"289","author":"Nande","year":"2022","journal-title":"Proc. R. Soc. B"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1128\/AAC.43.5.1144","article-title":"Efficacy of microencapsulated rifampin in Mycobacterium tuberculosis-infected mice","volume":"43","author":"Quenelle","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Gupta, P.K., Jahagirdar, P., Tripathi, D., Devarajan, P.V., and Kulkarni, S. (2023). Macrophage targeted polymeric curcumin nanoparticles limit intracellular survival of Mycobacterium tuberculosis through induction of autophagy and augment anti-TB activity of isoniazid in RAW 264.7 macrophages. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1233630"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1021\/acsinfecdis.4c00713","article-title":"Immunomodulatory Nanoparticles Induce Autophagy in Macrophages and Reduce Mycobacterium tuberculosis Burden in the Lungs of Mice","volume":"11","author":"Bekale","year":"2025","journal-title":"ACS Infect. Dis."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"101390","DOI":"10.1016\/j.nanoso.2024.101390","article-title":"Nano-engineered solutions for extensively drug-resistant tuberculosis (XDR-TB): A novel nanomedicine","volume":"40","author":"Singh","year":"2024","journal-title":"Nano Struct. Nano Objects"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e01636-21","DOI":"10.1128\/aac.01636-21","article-title":"Pharmacodynamics and bactericidal activity of bedaquiline in pulmonary tuberculosis","volume":"66","author":"Lyons","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"31891","DOI":"10.1038\/s41598-024-83408-1","article-title":"Formulation and optimisation of bedaquiline nanoemulsions for the potential treatment of multi drug resistant tuberculosis in paediatrics using quality by design","volume":"14","author":"Ajayi","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1164\/rccm.202012-4541OC","article-title":"Efficacy of long-acting bedaquiline regimens in a mouse model of tuberculosis preventive therapy","volume":"205","author":"Kaushik","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1093\/jac\/dkae309","article-title":"A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease","volume":"79","author":"Stemkens","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Y\u0131ld\u0131r\u0131m, M., and D\u00fczg\u00fcne\u015f, N. (2025). Liposome-Encapsulated Antibiotics for the Therapy of Mycobacterial Infections. Antibiotics, 14.","DOI":"10.3390\/antibiotics14070728"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Garcia-Contreras, L., Sethuraman, V., Kazantseva, M., and Hickey, A. (2021). Efficacy of combined rifampicin formulations delivered by the pulmonary route to treat tuberculosis in the guinea pig model. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13081309"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"13384","DOI":"10.3390\/molecules200713384","article-title":"Molecular docking and structure-based drug design strategies","volume":"20","author":"Ferreira","year":"2015","journal-title":"Molecules"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Abd-Algaleel, S.A., Abdel-Bar, H.M., Metwally, A.A., and Hathout, R.M. (2021). Evolution of the computational pharmaceutics approaches in the modeling and prediction of drug payload in lipid and polymeric nanocarriers. Pharmaceuticals, 14.","DOI":"10.3390\/ph14070645"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Javan Nikkhah, S., and Thompson, D. (2021). Molecular modelling guided modulation of molecular shape and charge for design of smart self-assembled polymeric drug transporters. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13020141"},{"key":"ref_165","first-page":"143","article-title":"Artificial intelligence and machine learning implemented drug delivery systems: A paradigm shift in the pharmaceutical industry","volume":"7","author":"Jena","year":"2024","journal-title":"J. Bio-X Res."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1039\/D4DD00104D","article-title":"Machine learning-guided high throughput nanoparticle design","volume":"3","author":"Grisoni","year":"2024","journal-title":"Digit. Discov."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1039\/D5PM00089K","article-title":"Artificial intelligence in smart drug delivery systems: A step toward personalized medicine","volume":"2","author":"Panchpuri","year":"2025","journal-title":"RSC Pharm."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/psp4.13008","article-title":"A physiologically-based pharmacokinetic model for tuberculosis drug disposition at extrapulmonary sites","volume":"12","author":"Ramachandran","year":"2023","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s40262-024-01363-6","article-title":"Predictions of bedaquiline central nervous system exposure in patients with tuberculosis meningitis using physiologically based pharmacokinetic modeling","volume":"63","author":"Mehta","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/psp4.13268","article-title":"Physiologically based pharmacokinetic modeling of drug\u2013drug interactions between ritonavir-boosted atazanavir and rifampicin in pregnancy","volume":"13","author":"Atoyebi","year":"2024","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Cicchese, J.M., Dartois, V., Kirschner, D.E., and Linderman, J.J. (2020). Both pharmacokinetic variability and granuloma heterogeneity impact the ability of the first-line antibiotics to sterilize tuberculosis granulomas. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.00333"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s44172-024-00296-z","article-title":"Computational multiphysics modeling of radioactive aerosol deposition in diverse human respiratory tract geometries","volume":"3","author":"Bartol","year":"2024","journal-title":"Commun. Eng."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.partic.2024.11.018","article-title":"Numerical investigations on the deposition characteristics of lunar dust in the human bronchial airways","volume":"97","author":"Jing","year":"2025","journal-title":"Particuology"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Visintainer, R., Fochesato, A., Boaretti, D., Giampiccolo, S., Watson, S., Levi, M., Reali, F., and Marchetti, L. (2025). stormTB: A web-based simulator of a murine minimal-PBPK model for anti-tuberculosis treatments. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1462193"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Reali, F., Fochesato, A., Kaddi, C., Visintainer, R., Watson, S., Levi, M., Dartois, V., Azer, K., and Marchetti, L. (2024). A minimal PBPK model to accelerate preclinical development of drugs against tuberculosis. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1272091"},{"key":"ref_176","first-page":"106","article-title":"Breaking barriers: The potential of nanosystems in antituberculosis therapy","volume":"39","author":"Canales","year":"2024","journal-title":"Bioact. Mater."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"e00284-23","DOI":"10.1128\/aac.00284-23","article-title":"Lung microenvironments harbor Mycobacterium tuberculosis phenotypes with distinct treatment responses","volume":"67","author":"Walter","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"215851","DOI":"10.1016\/j.ccr.2024.215851","article-title":"Coordination bonded stimuli-responsive drug delivery system of chemical actives with metal in pharmaceutical applications","volume":"510","author":"Kothawade","year":"2024","journal-title":"Coord. Chem. Rev."},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Krueger, G., Faisal, S., and Dorhoi, A. (2025). Microenvironments of tuberculous granuloma: Advances and opportunities for therapy. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1575133"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1128\/AAC.02243-12","article-title":"Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis","volume":"57","author":"Diacon","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"e00007-19","DOI":"10.1128\/AAC.00007-19","article-title":"Activity of a long-acting injectable bedaquiline formulation in a paucibacillary mouse model of latent tuberculosis infection","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_182","unstructured":"U.S. Food and Drug Administration (FDA) (2025, October 10). Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling\u2014Guidance for Industry, Available online: https:\/\/www.fda.gov\/media\/70837\/download?."},{"key":"ref_183","unstructured":"U.S. Food and Drug Administration (FDA) (2025, October 11). Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products\u2014Quality Considerations (Draft Guidance), Available online: https:\/\/public-inspection.federalregister.gov\/2018-08200.pdf."},{"key":"ref_184","unstructured":"European Medicines Agency (EMA) (2006). Reflection Paper on Nanotechnology-Based Medicinal Products for Human Use, European Medicines Agency. Available online: https:\/\/etp-nanomedicine.eu\/wp-content\/uploads\/2018\/10\/reflection-paper-nanotechnology-based-medicinal-products-human-use_en-1.pdf?."},{"key":"ref_185","unstructured":"World Health Organization (WHO) (2018). Active Tuberculosis Drug-Safety Monitoring and Management (aDSM), World Health Organization. Available online: https:\/\/cdn.who.int\/media\/docs\/default-source\/documents\/tuberculosis\/active-tb-drug-safety-monitoring-and-management-adsm3f6ba713-4a52-4076-9b1d-943bb96cfc55.pdf?sfvrsn=4a28fd4c_1&."},{"key":"ref_186","unstructured":"World Health Organization (WHO) (2023). Special Programme for Research and Training in Tropical Diseases (TDR). Training Guide for Trainers on Active Tuberculosis Drug Safety Monitoring and Management (aDSM), WHO\/TDR. Available online: https:\/\/tdr.who.int\/docs\/librariesprovider10\/adsm\/adsm-training-guide.pdf."},{"key":"ref_187","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) (2022). ICH Q13: Continuous Manufacturing of Drug Substances and Drug Products, ICH. Available online: https:\/\/database.ich.org\/sites\/default\/files\/ICH_Q13_Step4_Guideline_2022_1116.pdf?."},{"key":"ref_188","unstructured":"European Medicines Agency (EMA) (2020). Nanotechnology-Based Medicinal Products for Human Use: EU Horizon Scanning Report, European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/report\/nanotechnology-based-medicinal-products-human-use-eu-horizon-scanning-report_en.pdf?."},{"key":"ref_189","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) (2020). ICH Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management (Step 5), ICH. Available online: https:\/\/database.ich.org\/sites\/default\/files\/Q12_Guideline_Step4_2019_1119.pdf?."},{"key":"ref_190","unstructured":"U.S. Food and Drug Administration (FDA) (2025, October 29). Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management\u2014Guidance for Industry, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/q12-technical-and-regulatory-considerations-pharmaceutical-product-lifecycle-management-guidance?."},{"key":"ref_191","unstructured":"World Health Organization (WHO) (2025). Tuberculosis, World Health Organization. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/tuberculosis?."},{"key":"ref_192","unstructured":"World Health Organization (WHO) (2015). Global Programme on Tuberculosis and Lung Health: The End TB Strategy, World Health Organization. Available online: https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/the-end-tb-strategy?."},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-G\u00f3mez, F.D., Monferrer, D., Penon, O., and Rivera-Gil, P. (2025). Regulatory pathways and guidelines for nanotechnology-enabled health products: A comparative review of EU and US frameworks. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1544393"},{"key":"ref_194","unstructured":"(2017). Biological Evaluation of Medical Devices: Part 22: Guidance on Nanomaterials. Standard No. ISO\/TR 10993-22:2017. Available online: https:\/\/www.iso.org\/standard\/65918.html?."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"124","DOI":"10.37349\/ebmx.2024.00009","article-title":"Navigating regulatory challenges in molecularly tailored nanomedicine","volume":"1","author":"Singh","year":"2024","journal-title":"Explor. BioMat-X"},{"key":"ref_196","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) (2023). ICH Q2(R2): Validation of Analytical Procedures, ICH. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q2r2-guideline-validation-analytical-procedures-step-5-revision-1_en.pdf?."},{"key":"ref_197","unstructured":"World Health Organization (WHO) (2025). Active Tuberculosis Drug-Safety Monitoring and Management (aDSM)\u2014Programme Page, World Health Organization. Available online: https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/diagnosis-treatment\/treatment-of-drug-resistant-tb\/active-tb-drug-safety-monitoring-and-management-%28adsm%29?."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"109756","DOI":"10.1016\/j.compbiomed.2025.109756","article-title":"Utilizing machine learning for predicting drug release from polymeric drug delivery systems","volume":"188","author":"Aghajanpour","year":"2025","journal-title":"Comput. Biol. Med."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"100449","DOI":"10.1016\/j.nxmate.2024.100449","article-title":"Machine learning applied to the design and optimization of polymeric materials: A review","volume":"7","author":"Pai","year":"2025","journal-title":"Next Mater."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"240159","DOI":"10.1183\/16000617.0159-2024","article-title":"Digital twins for chronic lung diseases","volume":"33","author":"Gonsard","year":"2024","journal-title":"Eur. Respir. Rev."},{"key":"ref_201","unstructured":"World Health Organization (WHO) (2024). WHO Launches New Guidance on the Use of Targeted Next-Generation Sequencing Tests for the Diagnosis of Drug-Resistant Tuberculosis and a New Sequencing Portal, World Health Organization. Available online: https:\/\/www.who.int\/news\/item\/20-03-2024-who-launches-new-guidance-on-the-use-of-targeted-next-generation-sequencing-tests-for-the-diagnosis-of-drug-resistant-tb-and-a-new-sequencing-portal?."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"e03127-24","DOI":"10.1128\/spectrum.03127-24","article-title":"Targeted next-generation sequencing: A promising approach for Mycobacterium tuberculosis detection and drug resistance when applied in paucibacillary clinical samples","volume":"13","author":"Jin","year":"2025","journal-title":"Microbiol. Spectr."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00228-012-1429-9","article-title":"NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy","volume":"69","author":"Azuma","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_204","unstructured":"BioNTech SE (2025, November 01). Safety and Immune Responses After Vaccination with Two Investigational RNA-Based Vaccines against Tuberculosis in Healthy Volunteers, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05537038."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/1\/60\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T12:26:08Z","timestamp":1767356768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/1\/60"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":204,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["pharmaceutics18010060"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18010060","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]}}}